$TLRY

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.

Original reporting
Published Jul 29, 2026, 12:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23% — source image
Decision brief

The 30-second read

$TLRYNeutralMed
01

Why it matters

The immediate catalyst is the Q4 revenue beat versus consensus, but the earnings quality signal is mixed because EPS missed and beverage gross margin declined, even as adjusted EBITDA and FY26 revenue hit records.

02

Market read

After-hours shares rose 2.23% on the revenue surprise, but the EPS miss and margin decline suggest investors will scrutinize whether adjusted EBITDA guidance ($68M to $75M) can translate into improving profitability.

03

What to watch

Fuel surcharges and non-cash charges (stock-based comp, amortization) complicate the earnings quality read-through; traders may want to separate adjusted EBITDA trajectory from GAAP EPS volatility.

Relevance 8/10Novelty 7/10Timing: after-hours reaction to Q4 results reported Wednesday

Background

Tilray is a diversified cannabis and beverage company, with recent emphasis on distribution growth and the BrewDog acquisition.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Tilray reported Q4 net revenue of $281.7M, beating the $254.53M consensus by 10.7%, driving a 2.23% after-hours share rise.

Expected impact

Likely choppy follow-through: upside bias from revenue beat, capped by EPS miss and beverage gross margin decline.

Evidence & confidence

The article provides a concrete after-hours move tied to the revenue surprise, but also notes EPS missed by 76.2% and beverage gross margin fell from 39% to 36%, which can limit sustained upside.

Market effects

Read-through for cannabis and beverage peers: demand and distribution growth appear resilient, but integration or cost pressures may weigh on margins.

International medical cannabis revenue rose 34%, supporting a Europe-focused demand narrative for the sector.

BrewDog acquisition-related pro forma beverage platform (~$500M) may influence investor expectations for consolidation in global beverages.

Counterpoint

The revenue beat may be less durable if profitability continues to lag, given EPS miss and beverage gross margin decline tied to acquisition integration or cost pressures.

Key entities

  • Tilray Brands Inc.

    Reported Q4 net revenue of $281.7M (+10.7% vs consensus) and FY26 record net revenue of $915.5M, with EPS missing estimates.

  • BrewDog

    Acquisition cited as supporting beverage segment growth and a pro forma global beverage platform of about $500M.

  • Irwin D. Simon

    Chairman and CEO who characterized FY26 as a milestone for the diversified global platform.

Related articles

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

$TLRYMed

Tilray Brands Q4 Results: Adj. EPS beats estimate, sales up 25%

Tilray Brands (NASDAQ: TLRY) reported Q4 adjusted EPS of $0.05, versus a $(0.01) analyst consensus, and quarterly sales of $281.714 million versus $246.377 million expected. Sales rose 25.47% year over year to $281.714 million, while adjusted EPS fell 75% from $0.20. The company also noted Revolver’s Blood & Honey spirits launch in Texas.